Highest dose, obesity trial obesity-plus-diabetes trial (treatment-policy estimand): Semaglutide: 14.9% (STEP 1) 9.6% (STEP 2), a 5.3 point gap Tirzepatide: 20.9% (SURMOUNT-1) 14.7% (SURMOUNT-2), a 6.2 point gap Retatrutide: 25.0% (TRIUMPH-1) 20.8% (TRIUMPH-2 only efficacy-estimand currently reported so true gap is larger) It's still unclear the reason why we observe less weight loss in those with T2D
Yes, we prescribe Wegovy, Zepbound, Mounjaro, and Ozempic
Sitagliptin inhibited plasma DPP-4 activity, improved lipid tolerance, and increased plasma active GLP-1 in Dpp4 EC+/+ (BMT) mice (Figure 3, E and F)
Theyre also great for enjoying on their own to boost your fat intake
Understanding the unique pharmacological properties of these medications is crucial for a smooth transition and optimal results
The isoelectric point of semaglutide sits around pH 5.4, and degradation accelerates significantly between pH 4.5 and 5.5, which means that any formulation changes caused by temperature exposure can compound the problem by shifting the solution toward less stable conditions
